Principal Investigator

Sylvie Mader

Molecular Targeting in Breast Cancer Treatment

Subscribe to the newsletter

After training at the Paris École normale supérieure, the Université de Paris VI and at the Institut Pasteur, Sylvie Mader joined Pierre Chambon’s team at the Louis Pasteur Université in Strasbourg for a Ph.D. in Biochemistry, which she completed in 1991.

The Investigator then joined Nahum Sonenberg’s team, at McGill University, for postdoctoral training where she brought to light a control mechanism of translation involving eIF4E. She joined the Université de Montréal in 1995 and was recruited by the IRIC in 2005.

Principal Investigator, Molecular Targeting in Breast Cancer Treatment Research Unit, IRIC

Professor, Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal

Research unit on molecular targeting in breast cancer

Marcelle-Coutu Pavilion, 3306-7

Phone (office)
(514) 343-7166
Fax
(514) 343-7780
Email
sylvie.mader@umontreal.ca
Apply for a M.Sc. or a Ph.D.

Molecular Targeting in Breast Cancer Treatment

Sylvie Mader and her team try to identify the causes of the diversity of mammary tumors and how they impact the response to the drugs used in breast cancer treatment. The group strives to better understand the response or resistance mechanisms to the drugs used in breast cancer treatment and to identify new therapeutic targets to optimize its treatment.

Discover the research unit View the research team

Research topics

Publications

  • May 24, 2024

    Design, synthesis and antiproliferative activity of raloxifene/histone deacetylase inhibitor hybrids in breast cancer.

    Wang Y, Sauvage M, Diennet M, Weber S, Mader S, Gleason JL
    Eur J Med Chem 2024-05-24 ;274:116533

  • January 1, 2023

    The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.

    Vallet A, El Ezzy M, Diennet M, Haidar S, Bouvier M, Mader S
    J Biol Chem 2023-01-01 ;299( 1 ):102757

  • November 6, 2022

    CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3.

    Porras L, Gorse F, Thiombane NK, Gaboury L, Mader S
    Cancers (Basel) 2022-11-06 ;14( 21 ):

  • September 30, 2022

    Estrogens desensitize MCF-7 breast cancer cells to apelin-induced autophagy and enhanced growth under estrogen starvation: a possible implication in endocrine resistance.

    Bouchelaghem R, Mader S, Gaboury L, Messarah M, Boumendjel M, Boumendjel A
    Cell Mol Biol (Noisy-le-grand) 2022-09-30 ;68( 9 ):113-124

  • See all publications